Funding profile · Clinical trial software

Curebase

Fifty-nine million dollars reported, eighteen and a half million of it on file. The $40 million Series B that defines the company’s public funding story has no Form D behind it, and nothing has been filed since July 2021.

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

Reading the filings

1. The two company filings account for the whole pre-Series B total.$2,513,613 plus $16,350,000 is $18,863,613. When the Series A was announced, Lemberg told Crunchbase News the capital brought the total to $18.9 million, and the release said $19 million. Filings and statements agree to within about $40,000.
2. The Series A was announced at $15M and filed at $16.35M.Nineteen investors, about $860,526 each, fully sold with nothing remaining. The $1.35 million above the headline is the ordinary shape of a round that closed larger than it was pitched, or of earlier notes converting into it.
3. The $40 million Series B has no Form D.Nothing has been filed under CIK 0001757561 since July 1, 2021, and an EDGAR full text search for the company name returns exactly three Form D filings: two from Curebase, one from the Gaingels vehicle. Issuers selling under Section 4(a)(2) file no Form D at all, so silence is not evidence the round did not close. It does mean the $40 million figure, and the $59 million total built on it, rest on the announcement and the trade coverage of it, with no filed confirmation.
4. The syndicate priced in seven weeks before the news.Gaingels Curebase LLC took its first sale on March 18, 2022 and filed on March 25. The Series B was announced May 5. Twenty-five people put in $247,000, about $9,880 each, at a $1,000 minimum. Gaingels is named in the Series B announcement as a participant, so the vehicle is the retail end of an institutional round.
5. The board is only on record through 2021.The 2018 filing lists Thomas Lemberg alone. The 2021 filing adds Jeff Richards, matching the announcement that the GGV Capital managing partner would join the board. Because no Form D followed, the Series B board, including whatever seat Industry Ventures took, never appears in a filing. Lemberg left the chief executive seat in April 2025.
6. Headcount, not capital, is the clearest signal.Fierce Biotech put the company near 82 employees before the August 2023 layoffs that ended its clinical operations business. The Y Combinator directory lists 27 as of September 2026, and a Fort Lauderdale base rather than San Francisco: a two-thirds reduction against no new announced funding in four years.

Commercial signals

What to watch

• Any Form D. One is due within 15 days of the first sale of a Regulation D offering, and none has been filed in more than five years.
• Whether Sitebase is spun out. Its website is published under the name Sitebase Inc., its chief executive is Curebase’s, and no company by that name appears in SEC records.
• A named sponsor customer, or any revenue disclosure. The last figures the company published were 2022 activity counts.
• Whether the $59 million lifetime figure is ever restated. It has not moved since May 2022.

The Curebase story on Healthcare DiscoveryHealthcare Discovery

Related companies

• CareRev: Shared investor: Gaingels. A per diem shift marketplace that let hospitals book local nurses by the day
• Remedial Health: Shared investor: Gaingels. A Lagos company that sells wholesale medicine to Nigerian pharmacies and lends them the money to stock it
• Parallel Bio: Shared investor: Gaingels. Miniature human lymph nodes, grown from donated tissue and run side by side across hundreds of donors, used to test drugs and vaccines before anyone takes them
• Meru Health: Shared investor: Bold Capital. A 12 week virtual program pairing a licensed therapist with a heart rate variability biofeedback device

Sources

1. Public recordForm D, Curebase, Inc., CIK 0001757561SEC · Nov 2, 2018
2. Public recordForm D, Curebase, Inc., CIK 0001757561SEC · Jul 1, 2021
3. Public recordForm D, Gaingels Curebase LLC, CIK 0001917947SEC · Mar 25, 2022
4. Public recordEDGAR full text search for “Curebase,” three resultsSEC · Sep 22, 2026
5. Public recordClinicalTrials.gov, seven studies naming Curebase Inc.Accessed Sep 22, 2026
6. IndependentCurebase Inks $15M Series A For New Approach To Clinical TrialsCrunchbase News · May 25, 2021
7. IndependentDecentralized clinical trial startup Curebase raises $40MMobiHealthNews · May 5, 2022
8. IndependentCurebase axes some staff in pivot from clinical operations to trial softwareFierce Biotech · Aug 7, 2023
9. IndependentDecentralized Clinical Trials: Bust or Breakthrough?Applied Clinical Trials · Aug 2024
10. CompanyCurebase Unlocks Drug Development With Remote Clinical Trials; Raises $15MPR Newswire · May 25, 2021
11. CompanyCurebase Secures $40 Million in Series B FundingPR Newswire · May 5, 2022
12. CompanyCurebase Announces Important Leadership UpdateCurebase · Apr 9, 2025
13. CompanyCurebase Expands AI-Powered eClinical Platform and Launches SitebaseClinical Research News · Jan 30, 2026
14. DirectoryCurebase company listingY Combinator · Sep 22, 2026

Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Curebase. This page is not an offer to sell or a recommendation to buy any security.